Einstein Montefiore

1. Age ≥18 years old with advanced or metastatic stage solid tumors 2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1 and measurable disease per RECIST V1.1 (except for participants in dose escalation and prostate cancer participants) 3. Additional inclusion criteria for dose expansion cohorts: Participants with homologous recombination deficiency (HRD+) or known BRCA mutant Ovarian cancer a. Previously received at least 1 line of platinum containing chemotherapy and No progression or recurrent disease in 6 months from last platinum containing regimen. Participants with HRD+ or known breast cancer susceptibility gene (BRCA) mutant Triple-Negative Breast Cancer a. 0 - 1 prior platinum-containing regimen (any treatment setting) and received ≤ 3 prior regimens (advanced or metastatic setting). Participants with HRD+ or known BRCA mutant Prostate cancer 1. Chemotherapy-naïve or previously received ≤2 taxane-based regimens. 2. May have pre-or post-treatment with a novel androgen receptor targeted agent. Participants Small cell lung and gastric cancer a. Previously received ≤ 2 prior lines of therapy. Participants with HRD+ NSCLC, head and neck cancer, esophageal cancer and soft tissue sarcomas 1. Must have tumors with with HRD+ as centrally determined 2. Must have received at least 1 but not more than 3 prior lines of therapy. Treatment naïve patients with soft tissue sarcoma might be allowed if standard of care therapy is not suitable or available.

All participants 1. Prior exposure to a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor. 2. Refractory to platinum-based therapy. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.